A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics
NCT ID: NCT00067951
Last Updated: 2018-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
190 participants
INTERVENTIONAL
2003-10-17
2004-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
NCT00499707
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
NCT00379769
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
NCT00329225
Rosiglitazone to Reverse Metabolic Defects in Diabetes
NCT00094796
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
NCT00551564
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rosiglitazone/metformin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of Type II diabetes
* Prior treatment with diet and/or exercise alone, or less than 15 days of prior treatment with an oral anti-diabetic medication or insulin.
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Anniston, Alabama, United States
GSK Investigational Site
Chandler, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Encinitas, California, United States
GSK Investigational Site
Fullerton, California, United States
GSK Investigational Site
Los Banos, California, United States
GSK Investigational Site
Mission Viejo, California, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Melbourne, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Saint Cloud, Florida, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Fayetteville, Georgia, United States
GSK Investigational Site
Woodstock, Georgia, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Evansville, Indiana, United States
GSK Investigational Site
Newburgh, Indiana, United States
GSK Investigational Site
Slidell, Louisiana, United States
GSK Investigational Site
Jackson, Mississippi, United States
GSK Investigational Site
Chesterfield, Missouri, United States
GSK Investigational Site
Kansas City, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Kingston, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Rochester, New York, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Mogadore, Ohio, United States
GSK Investigational Site
Downingtown, Pennsylvania, United States
GSK Investigational Site
Warminster, Pennsylvania, United States
GSK Investigational Site
West Chester, Pennsylvania, United States
GSK Investigational Site
Johnson City, Tennessee, United States
GSK Investigational Site
Arlington, Texas, United States
GSK Investigational Site
Beaumont, Texas, United States
GSK Investigational Site
Bryan, Texas, United States
GSK Investigational Site
Corpus Christi, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Midland, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Seattle, Washington, United States
GSK Investigational Site
Spokane, Washington, United States
GSK Investigational Site
Wenatchee, Washington, United States
GSK Investigational Site
Camperdown, New South Wales, Australia
GSK Investigational Site
St Leonards, New South Wales, Australia
GSK Investigational Site
Wollongong, New South Wales, Australia
GSK Investigational Site
Kippa-Ring, Queensland, Australia
GSK Investigational Site
Woolloongabba, Queensland, Australia
GSK Investigational Site
North Adelaide, South Australia, Australia
GSK Investigational Site
Caulfield, Victoria, Australia
GSK Investigational Site
Fremantle, Western Australia, Australia
GSK Investigational Site
Perth, Western Australia, Australia
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Coquitlam, British Columbia, Canada
GSK Investigational Site
Langley, British Columbia, Canada
GSK Investigational Site
Moncton, New Brunswick, Canada
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Burlington, Ontario, Canada
GSK Investigational Site
Courtice, Ontario, Canada
GSK Investigational Site
Kitchener, Ontario, Canada
GSK Investigational Site
North Bay, Ontario, Canada
GSK Investigational Site
Oshawa, Ontario, Canada
GSK Investigational Site
Peterborough, Ontario, Canada
GSK Investigational Site
Peterborough, Ontario, Canada
GSK Investigational Site
Renfrew, Ontario, Canada
GSK Investigational Site
Stoney Creek, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Laval, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Plessisville, Quebec, Canada
GSK Investigational Site
Pointe-Claire, Quebec, Canada
GSK Investigational Site
Saint Insidore de Dorchester, Quebec, Canada
GSK Investigational Site
Saint-Marc-des-Carrieres, Quebec, Canada
GSK Investigational Site
Sainte Jerome, Quebec, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
GSK Investigational Site
Regina, Saskatchewan, Canada
GSK Investigational Site
Saskatoon, Saskatchewan, Canada
GSK Investigational Site
Auckland, , New Zealand
GSK Investigational Site
Auckland, , New Zealand
GSK Investigational Site
Christchurch, , New Zealand
GSK Investigational Site
Rotorua, , New Zealand
GSK Investigational Site
Wellington, , New Zealand
GSK Investigational Site
Pusan, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Uijeongbu-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Annotated Case Report Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
712753/004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.